A Universal Antibody-derived Targeting Agent

Overview

Journal Cell Biophys

Specialty Biophysics

Date 1993 Jan 1

PMID 7889540

Authors

R A Spooner

M P Deonarain

P Savage

A A Epenetos

Affiliations

Soon will be listed here.

Abstract

We report bacterial expression of a single-chain antibody (ScFv) reactive against the haptens 4-hydroxy-3 nitrophenylacetic acid (NP) and 4-hydroxy-3-iodo-5-nitrophenylacetic acid (NIP) that is suitable for targeting to mammalian cells in vitro in a novel two-step targeting strategy. Hapten-derivatized primary antibodies of known specificity, bound to target cells, can capture the ScFv. Specificity resides in the interaction of the primary targeting antibody with the target and the interaction of the ScFv for NP/NIP, since the ScFv does not bind cells and nonderivatized antibodies bound at cells cannot capture the ScFv. The ScFv described here can therefore be considered as a universal agent for delivery of drugs, toxins, or radionuclides to any cell type for which a previously characterized antibody exists.

References

Glockshuber R, Malia M, Pfitzinger I, Pluckthun A . A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry. 1990; 29(6):1362-7. DOI: 10.1021/bi00458a002. View

Yokota T, Milenic D, Whitlow M, Schlom J . Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992; 52(12):3402-8. View

Senter P, Saulnier M, Schreiber G, Hirschberg D, Brown J, Hellstrom I . Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci U S A. 1988; 85(13):4842-6. PMC: 280532. DOI: 10.1073/pnas.85.13.4842. View

Mariani M, Bracci L, Presentini R, Nucci D, Neri P, Antoni G . Immunogenicity of a free synthetic peptide: carrier-conjugation enhances antibody affinity for the native protein. Mol Immunol. 1987; 24(3):297-303. DOI: 10.1016/0161-5890(87)90148-9. View

Chaudhary V, Queen C, Junghans R, Waldmann T, Fitzgerald D, Pastan I . A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature. 1989; 339(6223):394-7. DOI: 10.1038/339394a0. View

Pack P, Pluckthun A . Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry. 1992; 31(6):1579-84. DOI: 10.1021/bi00121a001. View

Huston J, Levinson D, Tai M, Novotny J, Margolies M, Ridge R . Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A. 1988; 85(16):5879-83. PMC: 281868. DOI: 10.1073/pnas.85.16.5879. View

McCartney J, Lederman L, Drier E, Wu G, Batorsky R, Huston J . Biosynthetic antibody binding sites: development of a single-chain Fv model based on antidinitrophenol IgA myeloma MOPC 315. J Protein Chem. 1991; 10(6):669-83. DOI: 10.1007/BF01025718. View

Bagshawe K, Springer C, Searle F, Antoniw P, Sharma S, Melton R . A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer. 1988; 58(6):700-3. PMC: 2246864. DOI: 10.1038/bjc.1988.293. View

10.

Casadei J, Powell M, Kenten J . Expression and secretion of aequorin as a chimeric antibody by means of a mammalian expression vector. Proc Natl Acad Sci U S A. 1990; 87(6):2047-51. PMC: 53623. DOI: 10.1073/pnas.87.6.2047. View

11.

Sawyer J, Tucker P, Blattner F . Metal-binding chimeric antibodies expressed in Escherichia coli. Proc Natl Acad Sci U S A. 1992; 89(20):9754-8. PMC: 50211. DOI: 10.1073/pnas.89.20.9754. View

12.

Tai M, Levinson D, Wu G, Haber E, Oppermann H, Huston J . A bifunctional fusion protein containing Fc-binding fragment B of staphylococcal protein A amino terminal to antidigoxin single-chain Fv. Biochemistry. 1990; 29(35):8024-30. DOI: 10.1021/bi00487a005. View

13.

Paganelli G, Pervez S, Siccardi A, Rowlinson G, Deleide G, Chiolerio F . Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies. Int J Cancer. 1990; 45(6):1184-9. DOI: 10.1002/ijc.2910450632. View

14.

Colcher D, Bird R, Roselli M, HARDMAN K, Johnson S, Pope S . In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst. 1990; 82(14):1191-7. DOI: 10.1093/jnci/82.14.1191. View

15.

Milenic D, Yokota T, Filpula D, Finkelman M, Dodd S, Wood J . Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 1991; 51(23 Pt 1):6363-71. View

16.

Hogg P, Johnston S, Bowles M, Ponds S, Winzor D . Evaluation of equilibrium constants for antigen-antibody interactions by solid-phase immunoassay: the binding of paraquat to its elicited mouse monoclonal antibody. Mol Immunol. 1987; 24(7):797-801. DOI: 10.1016/0161-5890(87)90064-2. View

17.

Neuberger M, Williams G, Fox R . Recombinant antibodies possessing novel effector functions. Nature. 1984; 312(5995):604-8. DOI: 10.1038/312604a0. View

18.

Ward E, Gussow D, Griffiths A, Jones P, Winter G . Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature. 1989; 341(6242):544-6. DOI: 10.1038/341544a0. View

19.

Bird R, HARDMAN K, Jacobson J, Johnson S, Kaufman B, Lee S . Single-chain antigen-binding proteins. Science. 1988; 242(4877):423-6. DOI: 10.1126/science.3140379. View

20.

Hnatowich D, Virzi F, Rusckowski M . Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987; 28(8):1294-302. View